However, anti‐cancer clinical trials of FAK inhibitors show the limited single‐agent efficacy (Gan et al., 2012; Infante et al., 2012) and compensatory signaling has been found to be responsible for this phenomenon. This evidence concerns the gene PTK2 and cancer.